Xellia Pharmaceuticals acquires Fresenius Kabi’s manufacturing facility

Xellia acquires Fresenius Kabi’s manufacturing facility in Raleigh, US

10:05 AM, 8th July 2014
Xellia Pharmaceuticals acquires Fresenius Kabi’s manufacturing facility

COPENHAGEN, DENMARK: Xellia Pharmaceuticals, a specialty pharmaceutical company focusing on providing important anti-infective treatments against serious and often life-threatening infections, has acquired Fresenius Kabi’s dedicated lyophilized (freeze-dried) vial manufacturing facility in Raleigh, North Carolina, US. The deal includes a continuous manufacturing and supply agreement with Fresenius Kabi USA. Financial details are not disclosed.

The manufacturing site is located close to the world famous Research Triangle Park and is Xellia’s first facility in the US, significantly expanding the Company’s manufacturing capacity for injectable pharmaceutical products. Xellia intends to retain all 80 staff currently employed at the site and will continue to manufacture certain products at the site for Fresenius Kabi. In the future, Xellia plans to employ more staff as it expands the site further.

Xellia is increasingly moving on from its origins as a manufacturer of active pharmaceutical ingredients (APIs) to better serve its global customer base of over

500 pharmaceutical companies by supplying the finished dosage form (FDF) of its drugs. This acquisition is part of the latest phase of Xellia’s on-going global expansion plans which include an investment of $2.0 million at the Company’s Product and Innovation R&D Centre of Excellence in Zagreb, Croatia in May 2014.

“This agreement is part of our global strategy to optimize our manufacturing and supply network. Both companies are committed to assure a smooth and seamless transition for customers and employees. This transaction will have no impact on Fresenius Kabi’s abiliy to meet customer demand for the products we currently manufacture at the Raleigh site and we continue to work closely with the FDA to alleviate US drug shortages,” said John Ducker, President and CEO, Fresenius Kabi USA.


© Worldofchemicals News



Your Comments (Up to 2000 characters)
Please respect our community and the integrity of its participants. WOC reserves the right to moderate and approve your comment.

Related News

New formulation of chemotherapy drug to kill cancer cells effectively

GEORGIA, US: University of Georgia researchers have developed a new formulation of cisplatin, a common chemotherapy drug that significantly increases ...

Read more
AkzoNobel to sell paper chemicals business to Kemira for €153 million

AMSTERDAM, THE NETHERLANDS: AkzoNobel announced the intended sale of its global paper chemicals business to Kemira for €153 million. Paper Chemic ...

Read more
19,000 protein producing genes in humans, finds new study

LONDON, UK: In a new research, scientists have found the number of protein generating genes in humans to be 19,000 - 1,700 fewer than the most recent ...

Read more
New laser technology to identify chemical hazards

EDINBURGH, UK: A portable laser device is being developed at Heriot-Watt that can instantly identify chemical hazards, increasing the safety of emerge ...

Read more
ADM to acquire WILD Flavors

DECATUR, US: Archer Daniels Midland Company (ADM) is acquiring WILD Flavors GmbH, giving ADM the ability to offer food and beverage companies a compre ...

Read more
Squid’s teeth may find use in reconstructive surgery

WASHINGTON DC, US: Tentacles of squid are loaded with hundreds of suction cups, or suckers, and each sucker has a ring of razor-sharp “teeth&rdq ...

Read more
www.worldofchemicals.com uses cookies to ensure that we give you the best experience on our website. By using this site, you agree to our Privacy Policy and our Terms of Use. X